IL29570A - Preparations for the treatment of leukoma containing a history of 5, 01 - Epoxy - H5 - Dibenzo] a, d [Cyclohapthen - Google Patents
Preparations for the treatment of leukoma containing a history of 5, 01 - Epoxy - H5 - Dibenzo] a, d [CyclohapthenInfo
- Publication number
- IL29570A IL29570A IL29570A IL2957068A IL29570A IL 29570 A IL29570 A IL 29570A IL 29570 A IL29570 A IL 29570A IL 2957068 A IL2957068 A IL 2957068A IL 29570 A IL29570 A IL 29570A
- Authority
- IL
- Israel
- Prior art keywords
- dibenzo
- epoxy
- compositions
- treatment
- dihydro
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 15
- 208000010412 Glaucoma Diseases 0.000 title description 6
- NKHVNCLSTFMOTK-UHFFFAOYSA-N 16-oxatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,8,10,12,14-heptaene Chemical class O1C2C3=C(C1=CC1=C2C=CC=C1)C=CC=C3 NKHVNCLSTFMOTK-UHFFFAOYSA-N 0.000 title 1
- 230000000699 topical effect Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000001384 anti-glaucoma Effects 0.000 claims 2
- UOKCFJSKJHPUDQ-PWCSWUJKSA-N (8R,9R)-1-[3-(methylamino)propyl]-16-oxatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaen-8-ol Chemical compound O1C2(C3=C([C@@H]1[C@@H](C1=C2C=CC=C1)O)C=CC=C3)CCCNC UOKCFJSKJHPUDQ-PWCSWUJKSA-N 0.000 claims 1
- QAJBMPFDGJGKRN-UHFFFAOYSA-N N-[1-[3-(dimethylamino)propyl]-16-oxatetracyclo[7.6.1.02,7.010,15]hexadeca-2,4,6,10,12,14-hexaen-8-ylidene]hydroxylamine Chemical compound CN(CCCC12C3=C(C(C(C4=C1C=CC=C4)=NO)O2)C=CC=C3)C QAJBMPFDGJGKRN-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 5
- 239000000150 Sympathomimetic Substances 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229940096826 phenylmercuric acetate Drugs 0.000 description 5
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 5
- -1 sulfate Sodium bisulfite Boric acid Sodium borate Chemical compound 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- 230000001975 sympathomimetic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 230000003547 miosis Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 239000003604 miotic agent Substances 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010022949 Iris cyst Diseases 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62354067A | 1967-03-16 | 1967-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL29570A true IL29570A (en) | 1971-07-28 |
Family
ID=24498471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL29570A IL29570A (en) | 1967-03-16 | 1968-03-04 | Preparations for the treatment of leukoma containing a history of 5, 01 - Epoxy - H5 - Dibenzo] a, d [Cyclohapthen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3467756A (en:Method) |
| BE (1) | BE712259A (en:Method) |
| DE (1) | DE1667898A1 (en:Method) |
| FR (1) | FR7841M (en:Method) |
| GB (1) | GB1174882A (en:Method) |
| IE (1) | IE31971B1 (en:Method) |
| IL (1) | IL29570A (en:Method) |
| NL (1) | NL6802823A (en:Method) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| US6077839A (en) | 1992-03-19 | 2000-06-20 | Allergan Sales, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists |
| WO1995034302A2 (en) * | 1994-06-16 | 1995-12-21 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators |
| US6350780B1 (en) | 1995-07-28 | 2002-02-26 | Allergan Sales, Inc. | Methods and compositions for drug delivery |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3264342A (en) * | 1963-05-24 | 1966-08-02 | Geigy Chem Corp | Derivatives of 5h-dibenzo[a, d] cycloheptene |
| US3336340A (en) * | 1963-11-29 | 1967-08-15 | Rohm & Haas | Benzopyrans and process for the preparation thereof |
-
1967
- 1967-03-16 US US623540A patent/US3467756A/en not_active Expired - Lifetime
-
1968
- 1968-02-28 NL NL6802823A patent/NL6802823A/xx unknown
- 1968-03-04 IL IL29570A patent/IL29570A/en unknown
- 1968-03-04 IE IE249/68A patent/IE31971B1/xx unknown
- 1968-03-12 GB GB01980/68A patent/GB1174882A/en not_active Expired
- 1968-03-15 FR FR144115A patent/FR7841M/fr not_active Expired
- 1968-03-15 DE DE19681667898 patent/DE1667898A1/de active Pending
- 1968-03-15 BE BE712259D patent/BE712259A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IE31971L (en) | 1968-09-16 |
| GB1174882A (en) | 1969-12-17 |
| DE1667898A1 (de) | 1971-07-22 |
| FR7841M (en:Method) | 1970-05-25 |
| BE712259A (en:Method) | 1968-09-16 |
| IE31971B1 (en) | 1973-03-07 |
| NL6802823A (en:Method) | 1968-09-17 |
| US3467756A (en) | 1969-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0752847B1 (en) | Ophthalmic composition with decreased viscosity | |
| EP0389995B1 (en) | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension | |
| US20100041671A1 (en) | Methods for treating glaucoma | |
| SK281473B6 (sk) | Očný prípravok vo forme vodného roztoku na vonkajšie použitie | |
| JPH0696521B2 (ja) | 眼局所投与用眼圧降下剤 | |
| JPS6322021A (ja) | 眼圧制御剤 | |
| EP0338507A2 (en) | Use of mabuterol and related compounds for intraocular pressure adjustment | |
| US5554367A (en) | Compositions for treatment of glaucoma | |
| IL29570A (en) | Preparations for the treatment of leukoma containing a history of 5, 01 - Epoxy - H5 - Dibenzo] a, d [Cyclohapthen | |
| JPH10324640A (ja) | 炭酸脱水酵素阻害剤およびβ遮断剤を含有する局所用抗緑内障組成物 | |
| JP3094233B2 (ja) | （ｓ）−チモロール半水和物を含有する局所眼科治療用組成物及びその製造方法 | |
| RU2100020C1 (ru) | Средство для местного лечения глазной гипертензии и глаукомы и способ его получения | |
| GB2100599A (en) | Pharmaceutical preparation for treating glaucoma and ocular hypertension | |
| US4623664A (en) | Oil suspended phenylephrine | |
| US3920824A (en) | Stable ophthalmic formulation | |
| EP1137407B1 (en) | Ophthalmic formulation comprising a beta blocker and carbopol | |
| KR20230004582A (ko) | 에피나스틴 또는 그 염을 함유하는 수성 조성물 | |
| US3644647A (en) | Treatment of glaucoma employing 5-(3-methylaminopropyl - 5h - dibenzo(a b) cycloheptene | |
| EP0728480A1 (en) | Use of ifenprodil for treatment of elevated intraocular pressure | |
| JPH03106816A (ja) | 緑内障治療用点眼剤 | |
| EP0589020A4 (en) | Verapamil hcl formulation and other ophthalmic solutions with buffer system for ocular administration | |
| KR20210143254A (ko) | 마취 조성물 및 안구의 마취 방법 | |
| US3888985A (en) | Method and composition for lowering intraocular pressure | |
| WO2024034592A1 (ja) | Ｕｄｃａまたはその塩を含有する水性医薬組成物 | |
| CA2929965C (en) | Method and composition for treating glaucoma |